Eliminating hemostatic risk in plasma-derived biotherapeutic formulations

Plasma‑derived biotherapeutics face a persistent challenge: traditional ethanol‑based fractionation can introduce procoagulant contaminants such as FXIa and kallikrein activators, creating hemostatic risk and limiting both yield and safety. As global demand for IgG continues to outpace supply, safer, faster, and more stable manufacturing approaches are urgently needed.

Explore this resource to see how next‑generation ion‑exchange‑based purification technologies and integrated analytical workflows can remove trace clotting factors, enhance IgG recovery, and support the development of cleaner, more reliable plasma‑derived therapeutics.